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Novel 
neurotechnologies: 
intervening in the brain
a guide to the report
The report was produced by an interdisciplinary expert Working Party. 
In coming to its conclusions, the Working Party consulted a wide range 
of people, including people with experience of brain interventions, 
patient organisations, medical professionals and those involved in the 
research, development, regulation and commercialisation of novel 
neurotechnologies. 
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1Novel neurotechnologies: 
intervening in the brain
Serious brain disorders such as Parkinson’s disease, dementia, and brain damage caused by 
stroke already affect many people, and these numbers are set to rise as people live longer.  
Procedures that intervene in the brain offer the potential to help people with neurological and 
mental health conditions, especially those with severe symptoms where other treatments have 
not worked. They also have other possible applications for enhancement, recreational and 
military purposes.
This report sets out the potential benefits and risks of a number of technologies that intervene 
in the brain. 
•  The report focuses on four particular neurotechnologies, examining their potential uses, 
potential problems, and the economic influences shaping their availability. An ethical 
framework is developed around two fundamental considerations: the need for medical 
interventions to treat neurological and mental health conditions and the uncertainty about 
their benefits and risks.  
•  The report then considers 
the contexts in which novel 
neurotechnologies are 
developed, used, regulated 
and promoted: through the 
care of patients, research and 
innovation, regulation, non-
medical uses, and the media. 
It suggests how the ethical 
approach might guide the 
activities of those involved in 
each of these areas. 
Introduction
This guide outlines the main themes and 
recommendations that are discussed in the Nuffield 
Council on Bioethics’ report Novel neurotechnologies: 
intervening in the brain (published June 2013).  
What are ‘novel neurotechnologies’? 
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Illness or injury that causes damage to the brain can lead to impairments of memory, 
movement or consciousness, as well as conditions such as chronic pain. The brain has only a 
limited capacity to repair such damage itself.  
The following novel neurotechnologies have the potential to address some of the distressing 
and disabling effects of brain damage and mental health disorders by intervening in brain 
function. 
The report focuses on four types of neurotechnologies 
at different stages of development, ranging from those 
currently being researched, to established techniques 
that are being investigated for use in a wider range of 
conditions. 
Transcranial magnetic stimulation is 
one form of TBS.
Transcranial brain stimulation (TBS)
What is it? TBS is a term used to describe a group of interventions using devices that 
stimulate the brain using magnetic fields or weak electrical currents. These are non-invasive in 
that they involve attaching electrodes to the scalp or placing a magnetic coil next to the head. 
What is it used for? TBS technologies are commonly used in research and they are being 
explored as treatment options for a range of conditions, primarily depression but also 
addiction, stroke, tinnitus and others. There is also interest in using these devices to enhance 
mood or learning. 
What are the potential 
risks? TBS can result in 
minor localised discomfort, 
or in some cases headaches 
or temporary memory 
disturbances. 
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Deep brain stimulation (DBS) 
What is it? DBS is an invasive procedure requiring brain surgery to place electrodes in a 
specific region deep within the brain. A power source, also implanted in the body, supplies 
repeated pulses of current to stimulate that part of the brain.  
What is it used for? DBS is used to treat Parkinson’s disease and movement disorders such as 
dystonia. Researchers are exploring whether it could also be used to treat psychiatric disorders.
What are the potential risks? Risks resulting from the neurosurgery itself include infection 
and bleeding in the brain. There is some evidence linking DBS with unintended changes in 
mood, understanding and behaviour. 
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Brain-computer interfaces (BCIs) 
What are they? BCIs use electrodes - either implanted in the brain, or resting on the scalp 
- to record brain signals which are then translated into instructions for operating a computer-
controlled device. BCIs give users the opportunity to control devices, for example, by imagining 
movements. 
What are they used for? BCIs are being investigated for use facilitating movement and 
communication, so they offer significant potential to help paralysed individuals. Currently, 
invasive BCIs are only being used with patients in research settings. Some non-invasive BCIs are 
starting to become commercially available, for example as controls for computer games. 
What are the potential risks? Invasive BCIs carry risks associated with brain surgery. Most 
BCIs under investigation are non-invasive and very low risk, though little is yet known about 
the ways in which they might alter brain function after extended long-term use. 
Neural stem cell therapies
What are they? Neural stem therapies involve invasive procedures where stem cells are 
surgically injected into the brain. 
What are they used for? They seek to repair damage caused by stroke or by progressive 
brain conditions such as Parkinson’s disease. Current research into these techniques includes 
a clinical trial in stroke patients. It is too early to say whether this will provide an effective 
treatment.  
What are the potential risks? Risks resulting from neurosurgery itself include infection or 
bleeding in the brain. Other possible complications include pain or tumour development if the 
implanted cells do not grow or integrate as expected. Once the cells are implanted it may not 
be possible to remove them [Chapter 2].   
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Why do we need novel neurotechnologies? 
The high global incidence of brain disorders has considerable implications for economies. In 
the UK alone, there are around 800,000 people living with dementia, 300,000 people with 
disabilities caused by stroke, 127,000 people with Parkinson’s disease and millions who live 
with chronic pain.  
Challenges to funding for innovation
Issues that arise in relation to the funding and development pathways of novel 
neurotechnologies include: 
•  Private companies and investors are likely to focus on technologies that target the largest or 
most established markets. The needs of patients with rarer conditions or where health care 
resources are scarce may therefore receive less attention. 
•  The long timescales and uncertainties associated with developing stem cell based 
technologies may be seen by investors as too economically risky. 
•  Novel neurotechnologies are vulnerable to the ‘valley of death’ – a lack of funding to support 
the translation of early stage research into commercially viable products.
•  Prioritising fast returns on investment may encourage developers towards practices that 
might not best meet patients’ needs for access to safe and effective treatments, for example, 
developing elements of devices that might help increase sales, but do not necessarily 
enhance their benefits to patients. 
Economic drivers of innovation
There is a clear need for innovation to deliver effective 
treatments for disorders affecting the brain, but there are 
many obstacles to obtaining funding to achieve this.
We conclude...
It is vital that proportionate regulatory oversight encourages innovation, and directs 
investment and development towards the production of safe and effective products that 
meet genuine patient needs.  
Effective regulation alone may not be enough to promote equitable access to affordable 
treatments - innovative approaches to research, funding and commissioning are also 
needed [Chapter 3]. 
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Responsible research and innovation
The concept of ‘responsible research and innovation’ (RRI) has been widely adopted by 
policy-makers to encourage thinking about the public benefits of science and technology-
based research. We identified six key priorities in relation to RRI for novel neurotechnologies: 
Clearly identified need: In this case, a need for interventions to improve the lives of those 
with serious brain disorders. Development for the sake of novelty alone, without clear goals, 
should be avoided. 
Securing safety and efficacy: Protecting patient safety is a central aim of regulation, but 
risks must be assessed relative to any likely benefits. This highlights the value of assessing 
efficacy as part of product development.
Generating robust evidence: Small-scale studies, commercial influences, and bias  
towards publication of positive findings may all hinder the gathering of transparent, robust 
and balanced evidence. Alternative methods of linking and sharing evidence could help 
address this. 
Continuous reflexive evaluation: Reflecting, and reacting to, the directions towards 
which research is (potentially) travelling, can help avoid lock-in to innovation pathways that 
do not serve individual patient or public benefit.  
Coordinated interdisciplinary action: Coordination between the diverse professionals 
involved in novel neurotechnologies – e.g. engineers, surgeons and psychologists – will  
help to share understandings of, and visions for, how the technology could be developed 
and used. 
Effective and proportionate oversight: A proportionate balance must be struck between 
oversight that supports innovation, and that which protects patient safety. Sometimes 
statutory regulation will not be the best means of achieving this [Chapter 6]. 
There are six key elements to developing a systematic, 
responsible approach to the development of novel 
neurotechnologies.   
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Ethical framework
The brain has a special status in human life that distinguishes it from other organs. It plays 
a central role in our movement and communication, our ability to make our own decisions, 
and our understanding of ourselves and our relationships with others – thus in many ways 
affecting our ability to lead fulfilling lives. 
Intervening in the brain therefore raises important ethical and social concerns. 
This report sets out a three-part ethical framework to help 
evaluate and guide policy and practices relating to the 
development, funding, use, regulation and promotion of 
novel neurotechnologies.  
Foundational principles: beneficence and caution  
Given the suffering caused by brain disorders and an absence of other suitable treatments, 
there is a need for therapeutic applications of neurotechnologies. 
There is uncertainty about benefits and risks of these technologies, not only because of 
their novelty but also a lack of comprehensive understanding of how the brain functions and 
of the full range of work being done in this field.  
The special status of the brain therefore provides both a reason to exercise beneficence 
by finding ways to intervene when injury or illness causes brain disorders, and a reason for 
caution when we are uncertain what the effects of this will be. 
Key interests  
We identified five key interests that must be considered in relation to novel 
neurotechnologies:
• Protection of safety, taking into account risks alongside expected benefits.
•  Promotion of autonomy (both in the sense of supporting people’s capacity to make their 
own decisions and in the sense of protecting their sense of who they are). 
•  Protection of people’s privacy, bearing in mind that some devices may collect sensitive 
personal data. 
•  Promotion of equity both in terms of access to innovative products, and in addressing 
social stigma and discrimination.
• Promoting public understanding of and trust in novel neurotechnologies.    
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Virtues 
In describing the kinds of behaviours and approaches that are needed to protect and 
promote these interests, we highlight three virtues that are especially relevant in guiding 
the activities of all parties across a wide range of settings and applications of novel 
neurotechnologies. These virtues are:  
Inventiveness – expressed through technological innovation and by identifying ways of 
providing wider access to therapies.
Humility – acknowledging the limits of current knowledge and of our ability to use 
technologies to alleviate the harms of brain disorders. 
Responsibility – shown by robust research and clinical practices and by avoiding hype in 
communication about their potential uses. 
These virtues should be exemplified in the professional practices of all those involved in the 
development, funding, use, regulation and promotion of novel neurotechnologies, and 
supported by the structures and rules of the institutions within which they work [Chapter 4]. 
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Care of patients and research 
participants 
Decision making, consent and autonomy 
Given that novel neurotechnologies often address conditions that themselves impair decision-
making abilities, there may be difficulties in gaining informed consent from some patients 
and research participants. Moreover, the evidence on long-term and unintended effects of 
intervening in the brain is often not clear, and a lack of alternative treatments may give rise  
to desperation.
In line with the virtues of humility and responsibility (see the ethical framework on page 
9) it is important that medical professionals involved in providing treatment using novel 
neurotechnologies are open with patients in ways that include:
•  acknowledging and explaining the limits of current knowledge about the treatment 
outcomes that a patient can expect;
•  recognising instances where patients may benefit from counselling from qualified 
professionals other than their doctors; and 
•  avoiding characterising treatments as ‘last best hope’ where this is not justified.
An ethical approach to care is not just about ensuring 
patient safety - it should also support informed decision-
making and protect against harms such as undue privacy 
infringements or fostering unrealistic hopes.  
We conclude...
Those providing invasive treatments 
using neurotechnologies should 
be required to offer patients 
independent counselling, before 
consent is given, to provide an 
opportunity for patients and those 
close them to fully explore the 
implications and uncertainties of 
the treatment being offered. 
Protection from harm 
All of the novel neurotechnologies considered in this report involve some potential unintended 
consequences, but the scale of possible harm varies considerably between the different 
techniques (see pages 2 - 5). 
The lack of clear evidence about the ratio of risks to benefits presents challenges to responsible 
decision-making about patient care, both in treatment contexts and in the conduct of clinical 
investigations. 
Data collected by some devices (e.g. BCIs or in neurostimulation) about users’ brain functions 
may be valuable for the purposes of providing care or conducting research, but may also 
be sensitive and stigmatising. This raises concerns about adequate protection of privacy 
regarding the use of the data, and about the possibility of interference with the function of 
neurodevices. 
Research or experimental treatment?  
It is not always clear whether interventions or devices should be governed by rules that apply 
to treatment or to research, since the technologies used experimentally may fall in a middle 
ground between these. 
As well as ensuring protection for vulnerable patients, who are the most likely candidates for 
more experimental treatments, a particular concern is that knowledge and experience gained 
from experimental procedures should be collected and shared appropriately.        
We conclude...
NHS services using neurotechnologies should be required to adhere to national guidance on 
the use of new interventional procedures. 
Professional guidelines should be developed to ensure that patients who use private 
neurostimulation treatment services do so only following appropriate medical assessment. 
The Health Research Authority should develop guidance on the use of ‘sham’ neurosurgery 
controls in clinical trials of neural stem cell therapies. 
Researchers must state in advance what support will be offered to participants if access to 
neurodevices will finish when the study concludes. 
We conclude...
The General Medical Council, Health Research Authority and Medical Research Council 
should work together to produce professional guidance on responsible conduct in 
experimental treatment. 
Professional bodies such as the Association of British Neurologists, Society of British 
Neurological Surgeons and the Royal College of Psychiatrists should work together to 
establish publicly accessible registers to collect and link data on experiences of using novel 
neurotechnologies in healthcare settings [Chapter 5]. 
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Regulation 
The development and clinical use of these technologies falls into two distinct areas of 
regulation: 
•  The devices used in TBS, DBS and BCIs for medical purposes are regulated as medical 
devices, and can be marketed once they carry a ‘CE mark’ to indicate compliance with 
European law. 
•  Neural stem cell therapies are regulated as advanced therapeutic medicinal products 
(ATMPs) - more closely resembling the regulation of pharmaceuticals.
There are some marked differences between these two fields of regulation, such as:
•  ATMPs intended for the wider market are centrally approved at European level whereas 
medical devices are regulated at a national level. 
•  ATMPs have to undergo clinical trials to demonstrate that they are safe and effective. 
Medical devices can be marketed once they meet safety and performance standards, but 
manufacturers do not have to conduct clinical investigations to demonstrate treatment 
efficacy before receiving a CE mark.
•  Clinical investigations of ATMPs and medical devices are overseen by the national regulator; 
but in the UK, trials of neural stem cell therapies are also overseen by the Gene Therapy 
Advisory Committee.  
These combined factors mean that the journey of ATMPs from research to market is longer 
and more complex than for medical devices.  
Recommendations for regulation of medical devices 
The requirements for data about the functioning of medical devices before they are placed 
on the market are relatively light touch, though invasive devices (as used in DBS) must meet 
higher thresholds of evidence because they pose greater risks to patients’ safety. 
One advantage of this system is that devices can get to market relatively quickly, but there is 
a lack of transparency about the information on which approval decisions are based. The light 
touch approach to pre-market scrutiny of medical devices makes post-market surveillance for 
faults and adverse incidents all the more important. 
There are several key differences between regulation 
of neurodevices (as used in BCIs, DBS and TBS) and 
regulation of neural stem cell therapies, giving rise to 
different challenges.  
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Recommendations for regulation of ATMPs  
Given the health risks posed to patients if a neural stem cell therapy does not work as 
expected, robust regulation is vital. However, delays and regulatory complexity may present 
challenges and costs to developers and disincentives to investors.
Regulating therapies for individual patients and rare conditions 
There are several exceptional means by which patients can be treated with neurotechnologies 
that have not been generally approved to be used for their particular condition. These can 
offer valuable opportunities to address unmet health needs. However, oversight must be 
sufficiently robust for patients with rare conditions not to be exposed to disproportionate risks. 
We conclude...
Information relating to the approval of medical devices to enter the market, including the 
evidence used to show that neurodevices meet regulatory requirements, should be publicly 
accessible.
Approvals based on evidence relating to a similar neurodevice on the market, rather than 
clinical investigations of the new device, must be justified by the devices being sufficiently 
similar in effect.    
It should be compulsory for medical professionals to report any problems encountered 
in the use of neurodevices, supported by a scheme identifying newly approved devices. 
Information regarding adverse incidents and trends should be publicly accessible. 
We conclude...
There should be a responsible and proportionate approach to oversight that supports careful 
and appropriate scientific progress. Recent developments to streamline and reduce delays 
in the governance of stem cell therapies, and to promote dialogue between regulators and 
developers, are encouraging. 
We conclude...
Where neurodevices or ATMPs are approved for use on exceptional or non-routine grounds, 
it is important that the regulatory authorities have mechanisms for collecting information on 
when and why these treatments have been used and what the outcomes were and that this 
information can be shared to improve future good practice [Chapter 7]. 
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Non-medical uses: enhancement, 
gaming, military 
Research into the use of non-invasive TBS and BCI devices for ‘enhancement’ or gaming 
purposes is ongoing, and in some cases, products are being sold to consumers. Though these 
technologies do not present serious risks, their use for these purposes do not bring clear social 
benefits either. There is a need to understand better what the long-term effects of frequent 
private use of these devices might be, without research itself contributing to unnecessary 
interventions in the brain. 
Understanding the possible effects on the developing brain is particularly important as children 
and young people might be especially likely to use BCI games or to be encouraged to use 
neurodevices for educational ‘enhancement’ purposes. Furthermore, false or misleading claims 
about the benefits that novel neurotechnologies might offer risk exploiting consumers and 
undermining wider public trust in neurotechnologies. 
There is a potentially large market for novel 
neurotechnologies outside health care. These raise a 
number of ethical and social concerns. 
Enhancement – current knowledge     
Some small studies using non-invasive TBS procedures have reported improvements in 
participants’ performance in, for example, memory or language tasks. Whether and how 
these effects could be said to be ‘enhancements’ or would translate into practical benefits 
in the real world is unclear, as most studies are very limited in scale and the effects are small 
and transient. 
Gaming – current knowledge     
Non-invasive BCIs that record brain activity 
using electrodes placed on the scalp or 
forehead are being developed to enable 
players to control action in computer games. 
Some devices that claim to use BCIs are on 
the market, but these are currently limited in 
their functionality, and there are some doubts 
as to whether all of these are genuinely using 
brain signals, or are responding to facial 
movements.
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We conclude...
Institutional ethics committees should monitor proposals for research into non-medical uses 
of novel neurotechnologies to ensure their value and quality. Evidence gathered about non-
medical uses should be made available via publicly accessible registers. 
For the purposes of regulation, the European Commission should consider designating 
neurostimulation devices as medical devices, irrespective of the purpose for which they are 
marketed. 
The UK Departments of Education and the Royal College of Paediatrics and Child Health 
should issue advice to teachers and parents about the current evidence on the effectiveness 
of neurodevices for ‘enhancement’.
Observational research of children who already use neurotechnologies for gaming or 
learning is needed to assess the benefits and risks including effects on the developing brain. 
Military - current knowledge     
Aside from uses in treating war injuries, for example using BCIs for prosthetic limbs, military 
research is also being conducted into the possible use of neurotechnologies for non-medical 
applications, including: 
•  BCIs to enhance fighters’ effectiveness by improving perception and learning capabilities. 
•  BCIs to allow the remote control of weapons by brain signals. 
•  The use of neurostimulation or BCIs for interrogation purposes. 
Existing international conventions outlawing the use of biological and chemical weapons in 
war do not cover the use of neurodevices. However, the use of coercion in interrogation of 
prisoners is prohibited under international humanitarian law.
We conclude...
Advice should be issued to personnel in the armed forces and intelligence services 
highlighting that the use of neurodevices in interrogation is prohibited under the Geneva 
Conventions. 
Postgraduate teaching of neuroscientists should include ethical training, including awareness 
of the potential dual-use of neurotechnologies for hostile as well as peaceful purposes 
[Chapter 8]. 
Communication and the media 
The ways in which science and technology are presented in the media helps to shape public 
understanding and expectations. This in turn can affect attitudes, opinions, policy and perhaps 
investment decisions. 
There are obvious benefits to engaging the media with scientific issues: reaching new and 
potentially large audiences, promoting awareness, driving interest and possible investment 
in new technologies, for example. We welcome the recent increasing commitment to 
communication of science and technology. However, there are concerns about media 
coverage of new technologies in general. These include: 
• headlines that misrepresent research findings; 
• inaccuracy, mistakes or lack of detail in reporting studies; 
•  misuse of ‘balance’ – i.e. presenting a minority view in a way that creates a false impression 
of balance of opinion amongst scientists or the public;
•  focussing only on, or overstating, the possible benefits of a technology (and not reporting 
negative results, risks, long term uncertainties);
• over-reliance on a narrow range of sources; and
• uncritical reproduction of press releases.
The resulting misapprehensions of novel neurotechnologies amongst the public can be 
problematic for a number of reasons:  
•  They may instil false hope amongst patients by failing to report the limits or risks of current 
applications.
• They can affect patients’ ability to make informed treatment choices. 
• They could result in a loss of public trust in novel neurotechnologies. 
•  They could reinforce a notion that we are ‘just’ our brains.
 
The reporting of novel neurotechnologies should be 
accurate and evidence-based, and should take account 
of the personal and social impacts of misrepresenting or 
overstating their potential.   
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The role of scientists, press officers and journalists 
Scientists and press officers in research institutions are increasingly involved in public 
communications about science, but they face political, economic and institutional pressures 
to demonstrate important practical and economic impacts of their work. This, together 
with intense competition for science funding, can lead to a bias in favour of positive or 
newsworthy results.  
Science journalists are working in an increasingly competitive and fast-paced media 
environment. Expanding workloads mean less time to seek out and research new stories, 
which may go hand in hand with an increasing reliance on PR material. There is a trend for 
brief and rapid responses to new developments, accelerated by advances in social media.  
Responsible communication
All of the factors described above may in combination contribute to a ‘spiral’ of hype. 
Responsible reporting of novel neurotechnologies should be accurate and avoid undue 
speculation. Importantly it should take account of the possible impacts that framing stories in 
certain ways could have for patients and families. 
We conclude...
Researchers, press officers and journalists 
involved in the communication of the use of 
novel neurotechnologies should reflect on 
how their representations might contribute to 
hype, and exercise caution when describing 
the possible applications of a technology. 
Policy makers and higher education funding 
councils should consider the effects of 
the ‘impact agenda’ in university funding 
in contributing to hype about novel 
neurotechnologies. 
Companies and universities developing and 
promoting these products should consider 
their corresponding responsibilities carefully 
when seeking investment or promoting their 
products [Chapter 9].  
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Summary
Conditions affecting the brain such as Parkinson’s disease, dementia, stroke, 
chronic pain and depression affect many people. Technologies that intervene 
in the brain offer potential to help people with such conditions, especially 
those with severe symptoms where other treatments have proved ineffective. 
The technologies also have potential application in military contexts, and to 
commercial developers looking to exploit their use for enhancement and 
gaming purposes. 
This report looks at the benefits and risks presented by the development and 
use of a number of technologies that intervene in the brain. It considers the 
issues raised in relation to role of the brain in our self-perception, behaviour 
and personal relationships, the privacy of data about our brain activity, and 
the possible unintended effects of altering brain functions. Underlying these 
personal issues are also the wider social challenges of how regulation and 
innovation may be directed to developing safe and effective therapies and 
ensuring equitable access.
The report sets out an ethical framework to guide the practices of those 
involved in the development, regulation, use and promotion of novel 
neurotechnologies. The framework is based around two fundamental 
considerations: the need for medical interventions to treat brain conditions, 
and uncertainty about their benefits and risks. It suggests that the virtues of 
inventiveness, humility and responsibility capture the kinds of behaviours and 
attitudes that are most important in protecting and promoting the kinds of 
interests engaged by novel neurotechnologies. 
Recommendations are made as to how this ethical approach might guide 
policy and practice in a number of areas including:
• Care of patients and research participants 
• Responsible research and innovation            
• Regulation of medical technologies
• Non-medical applications 
• Communication and the media  
The full report and this guide are available to download or order from the 
Council’s website: www.nuffieldbioethics.org
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